# Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects

> **NCT01610427** · NA · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 22 (actual)

## Conditions studied

- AIDS
- AIDS Vaccines

## Interventions

- **PROCEDURE:** Blood sample collection

## Key facts

- **NCT ID:** NCT01610427
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-25
- **Primary completion:** 2012-10-30
- **Final completion:** 2012-10-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01610427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01610427, "Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01610427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*